Chromogranin a Measurement in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma: Screening for False Positives and a Prospective Follow-Up Study
Delphine Vezzosi(Université Toulouse III - Paul Sabatier), J. Guigay(Centre Antoine Lacassagne), Guillaume Cadiot(Centre Hospitalier Universitaire de Reims), Catherine Lombard‐Bohas(Hospices Civils de Lyon), Clarisse Dromain(University Hospital of Lausanne), Françoise Borson‐Chazot(Hospices Civils de Lyon), Éric Baudin(Institut Gustave Roussy), Jean‐Luc Raoul(Institut de Cancérologie de l'Ouest), Sophie Leboulleux(Geneva College), Michel Ducreux(Université Paris-Saclay), Emmanuel Mitry(Roche (Switzerland)), Agnès Laplanche(Institut Gustave Roussy), Philippe Ruszniewski(Inserm), Thomas Walter(University Hospital Waterford), Michèle d’Herbomez
Cited by 44
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k